An interventional study of Bu Zhong Yi Qi Tang and caramel dyed starch placebo in Myasthenia Gravis, sponsored by Cheng, yu-ting. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.
Sponsored by Cheng, yu-ting · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Myasthenia Gravis with a site in Taiwan — 6 open to participants now, 11 under way, 7 of them phase 3. Myasthenia Gravis · Taiwan.
Among the 21 studies in Myasthenia Gravis with a site in Taiwan, this one is the 11th largest by planned enrollment, is one of 4 that started in 2022, is one of 7 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 14th registered.
330 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.
Browse Myasthenia Gravis studies →6 of the 21 studies in Myasthenia Gravis with a site in Taiwan are open now. Recruiting first, the newest first:
Alexion Pharmaceuticals, Inc. · Sites in Taiwan, United States, Brazil and 2 more countries
Ages 6–17
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Sites in Taiwan, United States, Argentina and 22 more countries
Ages 18+
Yi Ting Yeh · Sites in Taiwan
Ages 20+
Yi Ting Yeh · Sites in Taiwan
Ages 20+ · Healthy volunteers
Janssen Research & Development, LLC · Sites in Taiwan, United States, Australia and 14 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 112 is above the median of 44 across 217 interventional studies indexed under Myasthenia Gravis.
Median enrollment 112 across the 21 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 21 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Cheng, yu-ting as lead sponsor.
Cheng, yu-ting has 1 study filed under Myasthenia Gravis — fewer than ten, so there is no comparison to draw.
2 of the studies in Myasthenia Gravis with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT06754020Yi Ting YehTCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis Compared to Healthy Controls | 2027-01-17 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Myasthenia Gravis with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Research Background: According to the Myasthenia Gravis Foundation of America (MGFA, 2015), the estimated prevalence of myasthenia gravis is 14-20 per 100,000 people, with a higher prevalence in young female individuals compared to males. However, as individuals age, especially after the age of 50, the prevalence in males becomes higher than in females. myasthenia gravis patients often experience varying degrees of disability, leading to the need for long-term medical care, medication, and lifestyle adjustments. This also gives rise to subsequent challenges in caregiving, affecting both the patients' families and society.
:This study aims to assess the effectiveness of using a combination of traditional Chinese and Western medicine,to improve the meridian energy and autonomic nervous system function of myasthenia gravis patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have taken Bu Zhong Yi Qi Tang
Drug: Bu Zhong Yi Qi Tang
Have taken caramel dyed starch placebo
Drug: caramel dyed starch placebo
The experimental group took 15g of Buzhong Yiqi Decoction concentrated powder, 3 times a day, 1 packet each time.
Also known as: TE202208013
The control group took 15 grams of caramel dyed starch placebo, 1 pack at a time, 3 times a day.
Also known as: starch placebo
meridian energy
After taking Buzhong Yiqi Decoction, the energy of the meridians can be balanced. Use a meridian measuring instrument to measure the meridians of the whole body and improve the energy of the meridians to the range of 40-60.
Time frame: 12 weeks
autonomic nervous system function
After taking Buzhong Yiqi Decoction, it can change the autonomic nervous system (ANS), reduce the sympathetic nerve energy, increase the parasympathetic nerve energy, and set the standard value of the autonomic nervous system activity between 40-60
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2022 (actual). Primary completion is estimated for Jun 2025, 35 months after the start.
Of 35 interventional studies with no phase under Myasthenia Gravis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 49. This study's planned 35 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bu-zhong-yi-qi-tang